IL107654A - Use of substituted-n-£££3, 4-dihydro-4-oxo-2-pyrimidyl) amino| alkyl|-4- piperidinyl| 2,2-dimethyl-7-benzofuran- and benzopyrancarboxamide for the preparation of 5-ht3 antagonist compositions, certain such novel compounds, pharmaceutical compositions containing them and their preparation - Google Patents

Use of substituted-n-£££3, 4-dihydro-4-oxo-2-pyrimidyl) amino| alkyl|-4- piperidinyl| 2,2-dimethyl-7-benzofuran- and benzopyrancarboxamide for the preparation of 5-ht3 antagonist compositions, certain such novel compounds, pharmaceutical compositions containing them and their preparation

Info

Publication number
IL107654A
IL107654A IL107654A IL10765493A IL107654A IL 107654 A IL107654 A IL 107654A IL 107654 A IL107654 A IL 107654A IL 10765493 A IL10765493 A IL 10765493A IL 107654 A IL107654 A IL 107654A
Authority
IL
Israel
Prior art keywords
formula
amino
methoxy
dihydro
compound
Prior art date
Application number
IL107654A
Other languages
English (en)
Other versions
IL107654A0 (en
Original Assignee
Siemens Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siemens Ag filed Critical Siemens Ag
Priority to IL11927393A priority Critical patent/IL119273A/xx
Publication of IL107654A0 publication Critical patent/IL107654A0/xx
Publication of IL107654A publication Critical patent/IL107654A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL107654A 1992-11-20 1993-11-18 Use of substituted-n-£££3, 4-dihydro-4-oxo-2-pyrimidyl) amino| alkyl|-4- piperidinyl| 2,2-dimethyl-7-benzofuran- and benzopyrancarboxamide for the preparation of 5-ht3 antagonist compositions, certain such novel compounds, pharmaceutical compositions containing them and their preparation IL107654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL11927393A IL119273A (en) 1992-11-20 1993-11-18 Enantiomerically enriched or enantiomerically pure cis-3-methoxy-4-aminopiperidines and their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20

Publications (2)

Publication Number Publication Date
IL107654A0 IL107654A0 (en) 1994-02-27
IL107654A true IL107654A (en) 1998-01-04

Family

ID=25526607

Family Applications (3)

Application Number Title Priority Date Filing Date
IL107654A IL107654A (en) 1992-11-20 1993-11-18 Use of substituted-n-£££3, 4-dihydro-4-oxo-2-pyrimidyl) amino| alkyl|-4- piperidinyl| 2,2-dimethyl-7-benzofuran- and benzopyrancarboxamide for the preparation of 5-ht3 antagonist compositions, certain such novel compounds, pharmaceutical compositions containing them and their preparation
IL11927393A IL119273A (en) 1992-11-20 1993-11-18 Enantiomerically enriched or enantiomerically pure cis-3-methoxy-4-aminopiperidines and their preparation
IL11927396A IL119273A0 (en) 1992-11-20 1993-11-18 3-Methoxy-4-amino-piperidines and their preparation

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11927393A IL119273A (en) 1992-11-20 1993-11-18 Enantiomerically enriched or enantiomerically pure cis-3-methoxy-4-aminopiperidines and their preparation
IL11927396A IL119273A0 (en) 1992-11-20 1993-11-18 3-Methoxy-4-amino-piperidines and their preparation

Country Status (31)

Country Link
US (2) US5674868A (th)
EP (1) EP0669919B1 (th)
JP (1) JP2830952B2 (th)
KR (1) KR0166661B1 (th)
AT (1) ATE176232T1 (th)
AU (1) AU680640B2 (th)
BG (1) BG62489B1 (th)
BR (1) BR9307477A (th)
CA (1) CA2149044C (th)
CZ (1) CZ287262B6 (th)
DE (1) DE69323322T2 (th)
DK (1) DK0669919T3 (th)
ES (1) ES2129615T3 (th)
FI (1) FI952458L (th)
GR (1) GR3029831T3 (th)
HU (2) HUT72740A (th)
IL (3) IL107654A (th)
LV (1) LV10956B (th)
MX (1) MX9307257A (th)
NO (2) NO307690B1 (th)
NZ (1) NZ257854A (th)
OA (1) OA10158A (th)
PL (1) PL176051B1 (th)
RO (1) RO115160B1 (th)
RU (1) RU2116072C1 (th)
SG (1) SG47488A1 (th)
SK (1) SK282378B6 (th)
TW (1) TW294595B (th)
UA (1) UA49792C2 (th)
WO (1) WO1994012494A1 (th)
ZA (1) ZA938676B (th)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
PT975327E (pt) 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv Uso de antagonistas de 5ht3 para estimular a lavagem intestinal
IL133225A (en) * 1997-07-11 2005-12-18 Janssen Pharmaceutica Nv (+)-Norcisapride useful for 5-HT3 and 5- HT4 mediated disorders
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
KR101118582B1 (ko) 2003-11-20 2012-02-27 얀센 파마슈티카 엔.브이. 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논
EP1709011B1 (en) 2003-11-20 2015-07-29 Janssen Pharmaceutica NV 7-phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
UA85593C2 (uk) 2004-06-30 2009-02-10 Янссен Фармацевтика Н.В. Похідні хіназолінону як інгібітори parp
EA014955B1 (ru) 2004-06-30 2011-04-29 Янссен Фармацевтика Н. В. Производные фталазина в качестве ингибиторов parp
MXPA06014541A (es) 2004-06-30 2007-03-23 Janssen Pharmaceutica Nv Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa.
AU2008223793B2 (en) 2007-03-08 2012-08-23 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
US8889866B2 (en) 2008-03-27 2014-11-18 Janssen Pharmaceutica, Nv Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
FI952458A7 (fi) 1995-05-19
SG47488A1 (en) 1998-04-17
ATE176232T1 (de) 1999-02-15
MX9307257A (es) 1994-05-31
HU211546A9 (en) 1995-12-28
US5674868A (en) 1997-10-07
NO307690B1 (no) 2000-05-15
TW294595B (th) 1997-01-01
AU5465994A (en) 1994-06-22
OA10158A (en) 1996-12-18
PL309045A1 (en) 1995-09-18
RU2116072C1 (ru) 1998-07-27
SK282378B6 (sk) 2002-01-07
CA2149044C (en) 2007-04-03
UA49792C2 (uk) 2002-10-15
FI952458A0 (fi) 1995-05-19
NO951980L (no) 1995-05-19
US5863923A (en) 1999-01-26
EP0669919A1 (en) 1995-09-06
HU9501476D0 (en) 1995-07-28
JP2830952B2 (ja) 1998-12-02
NO308530B1 (no) 2000-09-25
NZ257854A (en) 1997-04-24
AU680640B2 (en) 1997-08-07
BG62489B1 (bg) 1999-12-30
GR3029831T3 (en) 1999-06-30
KR0166661B1 (ko) 1999-01-15
ES2129615T3 (es) 1999-06-16
LV10956A (lv) 1995-12-20
NO951980D0 (no) 1995-05-19
BR9307477A (pt) 1999-06-29
WO1994012494A1 (en) 1994-06-09
SK67595A3 (en) 1995-11-08
DE69323322D1 (de) 1999-03-11
PL176051B1 (pl) 1999-03-31
CZ125895A3 (en) 1995-10-18
IL107654A0 (en) 1994-02-27
IL119273A (en) 2000-07-16
IL119273A0 (en) 1996-12-05
ZA938676B (en) 1995-05-19
NO995762L (no) 1995-05-19
FI952458L (fi) 1995-05-19
EP0669919B1 (en) 1999-01-27
NO995762D0 (no) 1999-11-24
DE69323322T2 (de) 1999-09-09
JPH08505840A (ja) 1996-06-25
RO115160B1 (ro) 1999-11-30
RU95113434A (ru) 1997-03-10
CA2149044A1 (en) 1994-06-09
DK0669919T3 (da) 1999-09-13
LV10956B (en) 1996-10-20
HUT72740A (en) 1996-05-28
BG99593A (en) 1995-12-29
CZ287262B6 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
EP0912552B1 (en) 2,4-diaminopyrimidine derivates as dopamine d4 receptor antagonists
US5077288A (en) 4-fluorobenzoic compounds with 5-HT2 - and α1 -antagonistic activities
AU680640B2 (en) Use of dimethylbenzofurans and dimethylbenzopyrans as 5-HT3 antagonists
JP2830936B2 (ja) 置換ｎ−（１−アルキル−３−ヒドロキシ−４−ピペリジニル）ベンズアミド類
AU724401B2 (en) Novel N-substituted 4-((4'-aminobenzoyl)-oxymethyl)-piperidines having gastric prokinetic properties
JP3269574B2 (ja) メタノアントラセン化合物、これを含有する神経精神障害を治療するための調剤学的組成物、およびこの化合物を製造するための方法および中間体
AU699152B2 (en) N-substituted piperidinyl bicyclic benzoate derivatives
EP0727421B1 (en) Agents for improving sleep
US4975439A (en) Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
HU204254B (en) Process for producing pharmaceutical compositions against diarrohe containing 4-(aroyl-amino)-piperidine-butaminide derivatives and for producing the new 4-(aroyl-amino)-piperidine derivatives
JP2002532480A (ja) モルホリノン及びモルホリン誘導体、ならびにその使用
EP0793663A1 (en) (thiophen-2-yl)-piperidin or tetrahydropyridin carboxamides
EP1448566B3 (en) Chemokine receptor antagonists and methods of use thereof
EP0784619B1 (en) Phenyl-oxo-alkyl-(4-piperidinyl)benzoate derivatives
MXPA97002363A (es) Derivados biciclicos de benzoato de piperidinilon-substituidos

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees